Candel Therapeutics (CADL) Stock Forecast & Price Target

Candel Therapeutics is a buy with a price target of $25, as the company is well-positioned for FDA approval of CAN-2409 in prostate cancer, with $120M in cash as of 4Q25 that can fund operations until 2028. The company also has upcoming data release of biomarker data in prostate and lung cancer trials, with CMC work on track for BLA submission in 4Q26. While there may be risks to achieving the price target, such as regulatory and manufacturing challenges, the company's strong pipeline and potential for FDA approval make it an attractive investment opportunity.

Candel Therapeutics is a development-stage biotechnology company facing potential challenges with significant capital investment requirements, dilution of shares, and fundraising difficulties if clinical data is negative or FDA approval is delayed or rejected. In addition, while key opinion leaders have highlighted the potential benefits of the company's off-the-shelf viral immunotherapy platforms and the product appears to be viable, the optimal number of administrations remains unclear and long-term survival rates will be a crucial factor in the success of the product. The company may also face challenges in the FDA review process, including potential advisory committee reviews and post-marketing commitments, which could delay potential commercialization.